Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction. Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it closed...
Enlaza Therapeutics’ $100 Million Series A Financing Round
Belite Bio’s $36 Million IPO
Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal. Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of...